Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 3×
“25% (fewer) of the mucosal microbial genes of healthy individuals [25].”
BackgroundInfluentialChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087 · cited 1×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 2×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“Human Bacteroidetes Firmicutes, Enterobacteriaceae Decrease Increase [163]”
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDiarrheagenic Escherichia coli
Nataro, J. P., & Kaper, J. B. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.142 · Cited by 5,006 · cited 1×
“Many studies in human IBD patients have reported the commensal bacteria association with the patient’s intestines; for example, an association of adherent/invasive Escherichia coli (AIEC), a normal gut flora of the Enterobacteriaceae group, has been found with CD [121].”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“Genome-wide association studies (GWAS) have identified more than 160 genetic loci associated with conferring protection from IBD or increased risk to IBD development [172].”
BackgroundRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Items 201–300 of 804
Longitudinal Microbiome Analysis in a Dextran Sulfate Sodium-Induced Colitis Mouse Model
Park, H., Yeo, S., Kang, S., & Huh, C. (2021) · Microorganisms · doi:10.3390/microorganisms9020370 · Cited by 35
“Disturbances in this homeostasis lead to a pathogenic state called dysbiosis by depleting beneficial microbes and changing microbial diversity [53,54].”
BackgroundZhang, Y., Mu, T., Yang, Y., Zhang, J., Ren, F., & Wu, Z. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab250 · Cited by 35
Esvap, E., & Ülgen, K. Ö. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00140 · Cited by 37
Song, L., Zhang, Y., Zhu, C., Ding, X., Yang, L., & Yan, H. (2021) · Advances in Medical Sciences · doi:10.1016/j.advms.2021.10.002 · Cited by 38
Lan, K., Yang, H., Zheng, J., Hu, H., Zhu, T., Zou, X., Hu, B., & Liu, H. (2022) · Food & Function · doi:10.1039/d2fo03424g · Cited by 37
Wanchaitanawong, W., Thinrungroj, N., Chattipakorn, S. C., Chattipakorn, N., & Shinlapawittayatorn, K. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109230 · Cited by 35
Ju, T., Song, Z., Qin, D., Cheng, J., Li, T., Hu, G., & Fu, S. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04433 · Cited by 34
Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbiosis
Colquhoun, C. M., Duncan, M., & Grant, G. (2020) · Diseases · doi:10.3390/diseases8020013 · Cited by 34
“Despite extensive study, the underlying reasons for dysbiosis remain unclear [205].”
BackgroundSustained Drought, but Not Short-Term Warming, Alters the Gut Microbiomes of Wild Anolis Lizards
Williams, C. E., Kueneman, J. G., Nicholson, D. J., Rosso, A. A., Folfas, E., Casement, B., Koyner, M. A. G., Neel, L. K., Curlis, J. D., McMillan, W. O., et al. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.00530-22 · Cited by 37
Fan, Y., Zhao, Q., Wei, Y., Wang, H., Ga, Y., Zhang, Y., & Hao, Z. (2023) · Antioxidants · doi:10.3390/antiox12051122 · Cited by 42
Interplay between engineered nanomaterials and microbiota
Zhang, Y., Mortimer, M., & Guo, L. (2020) · Environmental Science Nano · doi:10.1039/d0en00557f · Cited by 36
Petakh, P., Kamyshna, I. I., Nykyforuk, A., Yao, R., Imbery, J. F., Oksenych, V., Korda, M. M., & Kamyshnyi, O. (2022) · Viruses · doi:10.3390/v14030477 · Cited by 36
Oral Microbiome of Crohn’s Disease Patients With and Without Oral Manifestations
Hu, S., Mok, J. S. R., Gowans, M., Ong, D. E. H., Hartono, J. L., & Lee, J. W. J. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac063 · Cited by 41
Lee, H. L., Kim, J. M., Moon, J. H., Kim, M. J., Jeong, H. R., Go, M. J., Kim, H., Eo, H. J., Lee, U., & Heo, H. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010090 · Cited by 33
Microbes with higher metabolic independence are enriched in human gut microbiomes under stressPreprint
Veseli, I., Chen, Y. T., Schechter, M. S., Vanni, C., Fogarty, E. C., Watson, A. R., Jabrì, B., Blekhman, R., Willis, A. D., Yu, M., et al. (2023) · eLife · doi:10.7554/elife.89862 · Cited by 58
“proportion of variability in the taxonomic composition of the microbiota is unexplained, and the proportion of variability explained by disease status is low (Gevers et al. 2014; Schirmer et al. 2018; Lloyd-Price et al. 2019; Khan et al. 2019).”
InfluentialRubidium salt can effectively relieve the symptoms of DSS-induced ulcerative colitis
Zhao, L., Weng, W., Ni, M., Shen, H., Zhang, S., Chen, Y., Jia, R., Fan, L., Mao, Y., Qin, L., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117574 · Cited by 31
Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases
Anwer, E. K. E., Ajagbe, M., Sherif, M. A., Musaibah, A. S., Mahmoud, S., ElBanbi, A., & Abdelnaser, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010100 · Cited by 36
Probiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?
Filidou, E., & Kolios, G. C. (2021) · Pharmaceuticals · doi:10.3390/ph14111181 · Cited by 34
Risk Factors Associated with Recurrent Clostridioides difficile Infection
Negruţ, N., BUNGAU, S. G., Behl, T., Khan, S. A., Vesa, C. M., Bustea, C., Nistor-Cseppento, C. D., Rus, M., Pavel, F. M., & Ţiţ, D. M. (2020) · Healthcare · doi:10.3390/healthcare8030352 · Cited by 35
“Recent studies claim that intestinal microbiota is linked with the presence of chronic intestinal inflammation and, therefore, with inflammatory bowel diseases [47].”
BackgroundGut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools
Murgiano, M., Bartocci, B., Puca, P., Vincenzo, F. D., GAUDIO, A. D., Papa, A., Cammarota, G., Gasbarrini, A., Scaldaferri, F., & Lopetuso, L. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073059 · Cited by 31
“Despite their potential benefits, the use of antibiotics in IBD remains controversial due to adverse effects, the risk of dysbiosis, increased susceptibility to C. difficile infections, and the emergence of antibiotic-resistant strains [57,81].”
Modulatory Effect of Nicotinic Acid on the Metabolism of Caco-2 Cells Exposed to IL-1β and LPS
Santoru, M. L., Piras, C., Murgia, F., Spada, M., Tronci, L., Leoni, V. P., Serreli, G., Deiana, M., & Atzori, L. (2020) · Metabolites · doi:10.3390/metabo10050204 · Cited by 30
Parisio, C., Lucarini, E., Micheli, L., Toti, A., Khatib, M., Mulinacci, N., Calosi, L., Bani, D., Mannelli, L. D. C., & Ghelardini, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124304 · Cited by 30
Kumar, A., Teslova, T., Taub, E. M., Miller, J. D., & Lukin, D. J. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06439-4 · Cited by 31
Drug Targeting of Inflammatory Bowel Diseases by Biomolecules
Antunes, J. C., Seabra, C. L., Domingues, J., Teixeira, M. O., Nunes, C., Lima, S. A. C., Homem, N. C., Reis, S., de Amorim, M. T. P., & Felgueiras, H. P. (2021) · Nanomaterials · doi:10.3390/nano11082035 · Cited by 32
Yang, C., Long, D., Sung, J. J., Alghoul, Z., & Merlin, D. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091355 · Cited by 30
Andréasson, K., Lee, S. M., Lagishetty, V., Wu, M., Howlett, N., English, J., Hesselstrand, R., Clements, P. J., Jacobs, J. P., & Volkmann, E. R. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11387 · Cited by 31
Cardiovascular implications of inflammatory bowel disease: An updated review
Bhardwaj, A., Singh, A., Midha, V., Sood, A., Wander, G. S., Mohan, B., & Batta, A. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i11.553 · Cited by 33
Niu, Z., Liu, Y., Shen, R., Jiang, X., Wang, Y., He, Z., Li, J., Hu, Y., Zhang, J., Jiang, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155474 · Cited by 30
Microbiome Therapeutics: A Path Toward Sustainable Healthcare
Kumar, T., & Chauhan, N. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00010-3 · Cited by 29
New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites
Li, H., Pan, M., Li, Y., Cui, M., & Zhang, M. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.05.006 · Cited by 32
“Therefore, maintaining the balance between Th17 cells and Treg cells is essential for effective immune function in the gut [25].”
Estrogen receptor actions in colitis
Garcia-Vilarato, E., & Allred, C. D. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210010 · Cited by 30
The Association of Inflammatory Gut Diseases with Neuroinflammatory and Auditory Disorders
Kociszewska, D., & Vlajkovic, S. M. (2022) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1402008 · Cited by 32
“These strains of bacteria can cross the mucosal barrier, disturbing the epithelial lining [4,71], thus allowing bacterial metabolites and pathogens to translocate into the systemic circulation [4,25,39,156,162].”
BackgroundLi, Y., Han, Y., Wang, X., Yang, X., & Ren, D. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c06435 · Cited by 29
Yang, C., Du, Y., Li, Q., Liu, L., Zhao, L., Gao, C. J., Tang, Z., Zhang, X., Zhao, Y., & Yang, X. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07248 · Cited by 28
Microbiota-derived metabolites in inflammatory bowel disease
Guggeis, M. A., Harris, D. M. M., Welz, L., Rosenstiel, P. C., & Aden, K. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01046-9 · Cited by 35
“Although it has not conclusively been shown whether they are a cause or consequence, numerous studies in animal models of IBD have implicated a mechanistic impact of microbial metabolites and/or functions in onset and progression of the disease [20, 21].”
Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach
Sonkar, C., Kashyap, D., Varshney, N., Baral, B., & Jha, H. C. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00619-z · Cited by 29
Activation of Platelet NLRP3 Inflammasome in Crohn’s Disease
Zhang, G., Chen, H., Guo, Y., Zhang, W., Jiang, Q., Zhang, S., Han, L., Chen, S., & Xue, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.705325 · Cited by 34
“The current mainstream view believes that the occurrence of CD is related to genetics, environment, autoimmunity, nutrition and other factors (Singh et al., 2017; Turpin et al., 2018; Green et al., 2019; Khan et al., 2019; Schreiner et al., 2020).”
BackgroundXiao, T., Zhang, P., Feng, T., Lu, K., Wang, X., Zhou, S., & Qiang, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108034 · Cited by 32
Wu, X., Fu, S., Jiang, M., Wang, J., Tang, H., Fang, C., Li, W., & Fu, C. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115537 · Cited by 28
Zhang, Z., Wang, X., & Li, F. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1072151 · Cited by 33
“org Intestinal inflammation has been regarded as a serious, worldwide public health issue, and especially inflammatory bowel disease (IBD) is a persistent and worsening inflammatory gut disease (Khan et al., 2019).”
BackgroundArrè, V., Scialpi, R., Centonze, M., Giannelli, G., Scavo, M. P., & Negro, R. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00983-7 · Cited by 32
Yang, L., Li, X.-M., Duan, H.-Y., Yang, K., & Ye, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398652 · Cited by 36
Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma
Yu, Q., Wu, L., Ji, J., Feng, J., Dai, W., Li, J., Wu, J., & Guo, C. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s277870 · Cited by 27
Barnich, N., Rodrigues, M., Sauvanet, P., Chevarin, C., Denis, S., Goff, O. L., Faure-Imbert, D., Hanh, T., Roques, C. F., Chassaing, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094336 · Cited by 33
Diet, Probiotics and Physical Activity: The Right Allies for a Healthy Microbiota
Divella, R., Palma, G. D., Tufaro, A., Pelagio, G., Gadaleta‐Caldarola, G., Bringiotti, R., & Paradiso, A. (2021) · Anticancer Research · doi:10.21873/anticanres.15057 · Cited by 29
Hurtado‐Lorenzo, A., Honig, G., Weaver, S. A., Larkin, P. B., & Heller, C. A. (2021) · Crohn s & Colitis 360 · doi:10.1093/crocol/otab034 · Cited by 35
Traditional Chinese Medicine Alleviates Ulcerative Colitis via Modulating Gut Microbiota
Feng, W., Zhu, L., & Shen, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8075344 · Cited by 30
“Growing studies indicate that gut microbiota play a vital role in the immune homeostasis, especially in the ,17/Treg balance [71, 72].”
BackgroundMicrobes with higher metabolic independence are enriched in human gut microbiomes under stress
Veseli, I., Chen, Y. T., Schechter, M. S., Vanni, C., Fogarty, E. C., Watson, A. R., Jabrì, B., Blekhman, R., Willis, A. D., Yu, M., et al. (2025) · eLife · doi:10.1101/2023.05.10.540289 · Cited by 34
“…neither individual taxa nor broad changes in microbial community composition yield effective predictors of disease (Knox et al. 2019; M. Lee and Chang 2021), the role of gut microbes in the etiology of IBD – or the extent to which they are bystanders to disease – remains unclear (Khan et al. 2019).”
The Prophylactic Use of Bovine Colostrum in a Murine Model of TNBS-Induced Colitis
Menchetti, L., Curone, G., Filipescu, I. E., Barbato, O., Leonardi, L., Guelfi, G., Traina, G., Proietti, P. C., Riva, F., Casano, A. B., et al. (2020) · Animals · doi:10.3390/ani10030492 · Cited by 27
Probiotics and Their Metabolites Ameliorate Inflammatory Bowel Disease: A Critical Review
Liang, Y., Liu, M., Pu, J., Zhu, Z., Gao, Z., Zhou, Q., Gu, Q., & Li, P. (2020) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000046 · Cited by 28
“According to the incidence, severity, progression, and remission at different stages, IBD is mainly divided into ulcerative colitis (UC) and Crohn disease (CD)(2,3) and unfortunately, there is no cure.(4,5) Currently, researches on IBD mainly focus on the changes in intestinal microflora composition and function.”
BackgroundIntestinal Claudin-7 deficiency impacts the intestinal microbiota in mice with colitis
Ding, Y., Wang, K., Xu, C., Hao, M., Li, H., & Ding, L. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02100-8 · Cited by 26
“Consistent with the results, we also found a significant increase in Proteobacteria and a slight decrease in Firmicutes and Bacteroidota in CreW mice after DSS exposure, which was further enhanced in CreERT2 mice.”
BackgroundInfluentialSigala-Robles, R., Santiago‐López, L., Hernández‐Mendoza, A., Vallejo‐Córdoba, B., Mata‐Haro, V., Wall‐Medrano, A., & González-Córdova, A. F. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07382-2 · Cited by 26
Characterization of gut microbiota in adults with coronary atherosclerosis
Dong, Y., Xu, R., Chen, X., Yang, C., Jiang, F., Shen, Y., Li, Q., Fang, F., Li, Y., & Shen, X. (2023) · PeerJ · doi:10.7717/peerj.15245 · Cited by 28
“, 2019), inflammatory bowel disease (Khan et al., 2019), and rheumatic disease (Zhong et al.”
BackgroundZeeshan, M., Ain, Q., Weigmann, B., Story, D. T., Smith, B. R., & Ali, H. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100831 · Cited by 26
“DSS induction disturbed the microbial flora of the gut because of severe epithelial and luminal distortions [55] .”
Methodology for biomarker discovery with reproducibility in microbiome data using machine learning
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05639-3 · Cited by 31
“Several studies aim to identify variations in the gut microbiome and potential biomarkers to diagnose diseases and disorders such as inflammatory bowel disease (IBD) [2–5], type 2 diabetes (T2D) [6–9], autism spectrum disorder (ASD) [10–13], and some types of cancer [14–17], among others.”
BackgroundGoldiș, A., Dragomir, R., Mercioni, M. A., Goldiș, C., Sirca, D., Enătescu, I., Olariu, L., & Belei, O. (2025) · Microorganisms · doi:10.3390/microorganisms13051047 · Cited by 26
Gut mucosal and adipose tissues as health targets of the immunomodulatory mechanisms of probiotics
Ashaolu, T. J., & Fernández‐Tomé, S. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.04.040 · Cited by 27
Ulcerative Colitis Seems to Imply Oral Microbiome Dysbiosis
Molinero, N., Taladrid, D., Zorraquín‐Peña, I., de Celis, M., Belda, I., Mira, Á., Bartolomé, B., & Moreno-Arribas, M. V. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44040103 · Cited by 27
Alleviation of DSS-induced colitis in mice by a new-isolated Lactobacillus acidophilus C4
Liu, Q., Jian, W., Wang, L., Yang, S., Niu, Y., Xie, S., Hayer, K., Chen, K., Zhang, Y., Guo, Y., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1137701 · Cited by 28
Sun, R., Chao, C., Yu, J., Copeland, L., & Wang, S. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07046 · Cited by 27
Do, K.-H., Ko, S., Kim, K. B., Seo, K.-W., & Lee, W.-K. (2023) · Microorganisms · doi:10.3390/microorganisms11112750 · Cited by 27
Mun, D., Kang, M., Shin, M., Choi, H., Kang, A., Ryu, S., Unno, T., Maburutse, B. E., Oh, S., & Kim, Y. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00121-23 · Cited by 27
“Alterations in the community composition modify their metabolic output, resulting in the subsequent initiation of human diseases, including IBD (4).”
BackgroundInfluentialLi, H., Yang, W., Wu, X.-Z., Tian, L., Zhang, W., Tian, H., Xu, L., Huang, L., Guo, L., Li, X., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127987 · Cited by 25
Paudel, D., Nair, D. V. T., Joseph, G., Castro, R., Tiwari, A. K., & Singh, V. (2023) · Gastroenterology report · doi:10.1093/gastro/goae033 · Cited by 32
“In a healthy host, the diverse microbial composition plays a symbiotic role in the digestion of dietary fibers, synthesis of specific vitamins, and a favorable modulation of intestinal immune responses [23].”
Zhou, H., Zeng, X., Sun, D., Chen, Z., Chen, W., Fan, L., Limpanont, Y., Dekumyoy, P., Maleewong, W., & Lv, Z. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.606605 · Cited by 25
Wang, G., Chen, Y., Su, F., Xie, C., Xia, Y., & Ai, L. (2021) · Food & Function · doi:10.1039/d0fo02624g · Cited by 27
Hydrogen Regulates Ulcerative Colitis by Affecting the Intestinal Redox Environment
Li, J., Huang, G., Wang, J., Wang, S., & Yu, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s445152 · Cited by 24
Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems
Mishra, A. S., Ghosh, B., Malliappan, S. P., Dutta, G., & Vasanthan, M. V. M. (2026) · RSC Advances · doi:10.1039/d5ra05194k · Cited by 25
Ahmed, L. A., & Al‐Massri, K. F. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220222105004 · Cited by 26
Hu, Y., Ye, Z., She, Y., Li, L., Wu, M., Qin, K., Li, Y., He, H., Hu, Z., Yang, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.844961 · Cited by 30
“The dysbiosis of intestinal microbiota in UC patients is characterized by decreased abundance of beneficial bacteria, increased pathogenic bacteria and opportunistic pathogens (Khan et al., 2019).”
BackgroundWilson, E. J., Natesh, N. S., Ghadermazi, P., Pothuraju, R., Marudhupandiyan, S., Prajapati, D. R., Pandey, S., Kaifi, J. T., Dodam, J. R., Bryan, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010539 · Cited by 25
“Deviation in the gut flora composition is involved in multiple disease pathologies, including IBD [16].”
BackgroundTang, W., Huang, Y., Shi, P., Wang, Y., Zhang, Y., Xue, A., Tang, Z., Hu, W., Sun, H., Zhang, P., et al. (2020) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1938 · Cited by 25
Ni, H., Chen, Y., Xia, W., Wang, C., Hu, C., Sun, L., Tang, W., Cui, H., Shen, T., Liu, Y., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab094 · Cited by 25
Hou, K., Wu, Z., Chen, Y., Zhu, D., Zheng, Y., & Ali, K. B. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210929164930 · Cited by 24
Rectal swabs are a reliable method of assessing the colonic microbiome
Turner, G. A., O’Grady, M. J., Hudson, D. T., Morgan, X. C., Frizelle, F., & Purcell, R. V. (2022) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2022.151549 · Cited by 23
Lei, Z., Yang, L., Lei, Y., Yang, Y., Zhang, X., Song, Q., Chen, G., Liu, W., Wu, H., & Guo, J. (2021) · Toxicology · doi:10.1016/j.tox.2021.152799 · Cited by 24
The effect of a hydrolyzed protein diet on the fecal microbiota in cats with chronic enteropathy
Kathrani, A., Yen, S., Swann, J. R., & Hall, E. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-06576-y · Cited by 25
Old but Fancy: Curcumin in Ulcerative Colitis—Current Overview
Pituch, A., Dembiński, Ł., & Banaszkiewicz, A. (2022) · Nutrients · doi:10.3390/nu14245249 · Cited by 24
Immune response modulation in inflammatory bowel diseases by Helicobacter pylori infection
Balani, G. F., Cortez, M. D. S., Freitas, J. E. P. D. S., de Melo, F. F., Zarpelon-Schutz, A. C., & Teixeira, K. N. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i30.4604 · Cited by 24
Yu, B., Lu, Z., Zhong, S., & Cheong, K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1332105 · Cited by 27
“…disease, Alzheimer’s disease, asthma, and even alters how the host responds to drugs in the treatment of diseases (Ley et al., 2005; Arrieta et al., 2015; Hu et al., 2016; Leiva Gea et al., 2018; Bárcena et al., 2019; Khan et al., 2019; Sarkar and Banerjee, 2019; Contarino et al., 2023).”
BackgroundGuo, Q., Ye, C., Li, T., Huang, J., Li, J., Zhang, Z., & Qu, Y. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01613-9 · Cited by 24
“Recently, increasing attention has been attributed to studying gut microbiota, which is closely related to human and animal inflammatory diseases, such as bovine mastitis [6], Qing Guo and Ye Cheng These authors contributed equally to this work. pneumococcal pneumonia [7], enteritis [8].”
Liu, Z., Wu, S., Zhang, W., Cui, H., Zhang, J., Yin, X., Zheng, X. W., Shen, T., Ying, H., Chen, L., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117394 · Cited by 23
Gut virome: New key players in the pathogenesis of inflammatory bowel disease
Hetta, H. F., Ahmed, R. F., Ramadan, Y. N., Fathy, H., Khorshid, M., Mabrouk, M. M., & Hashem, M. (2024) · World Journal of Methodology · doi:10.5662/wjm.v15.i2.92592 · Cited by 22
Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission
Shute, A., Bihan, D. G., Lewis, I. A., & Nasser, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.917197 · Cited by 23
Microbiota as key factors in inflammatory bowel disease
White, Z., Cabrera, I., Kapustka, I., & Sano, T. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1155388 · Cited by 24
Ebrahiminejad, A., Sepahi, A. A., Yadegar, A., & Meyfour, A. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04576-1 · Cited by 22
“As no definitive treatment is currently available for this disease, it is important to identify and safe strategies to improve gut microbiota structure and function, and modulate immune system responses to manage IBD [41].”
BackgroundCortes, G. M., Marcialis, M. A., Bardanzellu, F., Corrias, A., Fanos, V., & Mussap, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.856165 · Cited by 22
The Microbiome and Its Potential for Pharmacology
Chavira, A., Belda‐Ferre, P., Kościółek, T., Ali, F., Dorrestein, P. C., & Knight, R. D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_317 · Cited by 22
Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis
Cardoneanu, A., Mihai, C., Rezuş, E., Burlui, A., Popa, I. V., & Prelipcean, C. C. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-2823 · Cited by 24
“The results of the published studies have demonstrated that IBD dysbiosis is characterized by a reduction in the diversity of bacterial species (especially anaerobic bacteria) followed by an increase in the concentration of entero-adherent bacteria [10-12].”
ResultKirby, T. O., Ochoa‐Repáraz, J., Roullet, J., & Gibson, K. M. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.12.289 · Cited by 22
Ijaz, M. U., Ahmed, A., Al‐Ghanim, K. A., Al-Misned, F. A., Riaz, M. N., Kaimkhani, Z. A., & Mahboob, S. (2023) · Toxics · doi:10.3390/toxics11020110 · Cited by 20
Microbiome and Its Dysbiosis in Inborn Errors of Immunity
Sharma, M., Dhaliwal, M., Tyagi, R., Goyal, T., Sharma, S., & Rawat, A. K. (2023) · Pathogens · doi:10.3390/pathogens12040518 · Cited by 20
Monika, P., Chandraprabha, M. N., Krishna, R. H., Satish, H., & Kumar, S. G. (2023) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2023.100540 · Cited by 21
Qiu, S.-M., Veeraperumal, S., Tan, K., Zhong, S., & Cheong, K. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106005 · Cited by 20
Fernández‐Veledo, S., Grau‐Bové, C., Notararigo, S., & Huber‐Ruano, I. (2025) · Current Opinion in Microbiology · doi:10.1016/j.mib.2025.102599 · Cited by 24
Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
Cherkasova, V., Kovalchuk, O., & Kovalchuk, I. (2021) · Cancers · doi:10.3390/cancers13174353 · Cited by 20
Prospero, L., Riezzo, G., Linsalata, M., Orlando, A., D’Attoma, B., Masi, M. D., Martulli, M., & Russo, F. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01820-7 · Cited by 20
“Abbreviations BMI: Body mass index; DAO: Diamine oxidase; EDTA: Ethylen-diamine-tetraacetic; EMA: Anti-endomysium; GI: Gastrointestinal; GSI: Global score index; GSRS: Gastrointestinal Symptom Rating Scale; HC: Healthy controls; HS: High somatization; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome; IBS…”
BackgroundInfluentialChang, C., Liu, C., Su, I.-C., Lee, Y., Yeh, H., Chen, W.-C., Yu, C.-J., Kao, W., Liu, Y., & Huang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911422 · Cited by 20
Thipart, K., Gruneck, L., Phunikhom, K., Sharpton, T. J., Sattayasai, J., & Popluechai, S. (2022) · International Microbiology · doi:10.1007/s10123-022-00309-x · Cited by 20
Ispas, S., Tuta, L. A., Botnarciuc, M., Ispas, V., Staicovici, S., Ali, S., Twakor, A. N., Cojocaru, C., Herlo, A., & Petcu, A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111602 · Cited by 24
“…bowel disease, there is an observed decrease in fecal short-chain fa tt y acid concentrations, as well as a decline in the abundance of Firmicutes and Bacteroidetes [52]. fecal short-chain fatty acid concentrations, as well as a decline in the abundance of Firmicutes and Bacteroidetes [52].”
Background
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.